Abstract
Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cells. Herpes simplex virus (HSV) is a promising agent for oncolytic virotherapy due to its broad cell tropism and the identification of mutations that favor its replication in tumor over normal cells. However, these attenuating mutations also tend to limit the potency of current oncolytic HSV vectors that have entered clinical studies. As an alternative, vector retargeting to novel entry receptors has the potential to achieve tumor specificity at the stage of virus entry, eliminating the need for replication-attenuating mutations. Here, we summarize the molecular mechanism of HSV entry and recent advances in the development of fully retargeted HSV vectors for oncolytic virotherapy. Retargeted HSV vectors offer an attractive platform for the creation of a new generation of oncolytic HSV with improved efficacy and specificity.
Keywords: Cancer, gene therapy, herpes simplex virus, oncolytic virus, targeting, vector, virotherapy, virus entry.
Current Cancer Drug Targets
Title:Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens
Volume: 18 Issue: 2
Author(s): Hiroaki Uchida*, Hirofumi Hamada, Kenji Nakano, Heechung Kwon, Hideaki Tahara, Justus B. Cohen and Joseph C. Glorioso
Affiliation:
- Division of Bioengineering, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo,Japan
Keywords: Cancer, gene therapy, herpes simplex virus, oncolytic virus, targeting, vector, virotherapy, virus entry.
Abstract: Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cells. Herpes simplex virus (HSV) is a promising agent for oncolytic virotherapy due to its broad cell tropism and the identification of mutations that favor its replication in tumor over normal cells. However, these attenuating mutations also tend to limit the potency of current oncolytic HSV vectors that have entered clinical studies. As an alternative, vector retargeting to novel entry receptors has the potential to achieve tumor specificity at the stage of virus entry, eliminating the need for replication-attenuating mutations. Here, we summarize the molecular mechanism of HSV entry and recent advances in the development of fully retargeted HSV vectors for oncolytic virotherapy. Retargeted HSV vectors offer an attractive platform for the creation of a new generation of oncolytic HSV with improved efficacy and specificity.
Export Options
About this article
Cite this article as:
Uchida Hiroaki*, Hamada Hirofumi, Nakano Kenji, Kwon Heechung, Tahara Hideaki, Cohen B. Justus and Glorioso C. Joseph, Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170206105855
DOI https://dx.doi.org/10.2174/1568009617666170206105855 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Threat Posed by Persistent Organochlorine Pesticides and their Mobility in the Environment
Current Organic Chemistry GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges
Current Drug Targets Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued) Regulatory T Cells and Skin Tumors
Recent Patents on Inflammation & Allergy Drug Discovery SNPs of Metabolic Syndrome are Associated with Benign Prostatic Hyperplasia Development and Progression in Chinese Population
Current Bioinformatics Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry Editorial [ Neuropeptide Y Receptors as Targets in Drug Discovery Guest Editor: Ambikaipakan Balasubramaniam ]
Current Topics in Medicinal Chemistry Poly(ADP-ribose): Structure, Physicochemical Properties and Quantification In Vivo, with Special Reference to Poly(ADP-ribose) Binding Protein Modules
Current Protein & Peptide Science Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology PAI-1 as a Target in Kidney Disease
Current Drug Targets System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Model Checking a Synchronous Diabetes-Cancer Logical Network
Current Bioinformatics Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design The Importance of Stereochemistry on the Actions of Vitamin D
Current Topics in Medicinal Chemistry Novel Target Identification Technologies for the Personalised Therapy of Type II Diabetes and Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)